SCHEMBL15936752

SCHEMBL15936752

CC(C)(C)OC(=O)NCCn1cc(-c2ccccc2Cl)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 2/20 0.46
MALT1 Q9UDY8 1/20 0.45
CREBBP Q92793 1/20 0.43
DRD2 P14416 3/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.43
ATM Q13315 1/20 0.43
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
ACACB O00763 1/20 0.42
ACACA Q13085 1/20 0.42
STK17B O94768 1/20 0.41
STK17A Q9UEE5 1/20 0.41
SCN9A Q15858 1/20 0.41
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15924834 0.82 CREBBP (0.49) PDK2CREBBPLMNAHPGDEGLN1
SCHEMBL30142919 0.82 PDK2 (0.43) PDK2MALT1DRD2ACACBACACA
SCHEMBL16434067 0.81 CREBBP (0.44) PDK2CREBBPHPGDVEGFAFLT1
SCHEMBL30606022 0.81 ALOX5AP (0.42) PDK2MALT1DRD2ACACBACACA
SCHEMBL31436567 0.81 ALOX5AP (0.42) PDK2MALT1DRD2ACACBACACA
SCHEMBL31627121 0.81 DRD2 (0.44) PDK2MALT1DRD2ACACBACACA
SCHEMBL30606133 0.80 SUV39H2 (0.41) PDK2MALT1DRD2STK17BSTK17A
SCHEMBL31436646 0.80 SUV39H2 (0.41) PDK2MALT1DRD2STK17BSTK17A
SCHEMBL9977832 0.80 CREBBP (0.42) PDK2MALT1CREBBPDRD2POLB
SCHEMBL17998112 0.78 CACNA1G (0.49) DRD2CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3495359-A1 FLAP MODULATORS Janssen Pharmaceutica NV (BE) 2019-06-12 EP disclosed
EP-3070085-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-01-09 EP disclosed
US-9745328-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2017-08-29 US disclosed
EP-3070085-A1 FLAP MODULATORS Janssen Pharmaceutica N.V. (BE) 2016-09-21 EP disclosed
US-20150376212-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-12-31 US disclosed
WO-2014121055-A2 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376212-A1 FLAP MODULATORS FEN1, PGF, TBXA2R PDK2 1666/4885MALT1 215/4885CREBBP 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.